Context-Dependent Signaling Network of Ginsenoside Rg2: A Molecular Basis for Its Bidirectional Pharmacological...

Ginsenoside Rg2 (G-Rg2) is a key protopanaxatriol-type saponin from Panax ginseng. Increasing evidence has shown that G-Rg2 exerts pharmacological effects such as neuroprotection, immune regulation, anti-inflammation and inhibition of tumor proliferation by reducing inflammatory response, blocking apoptotic cascade and regulating autophagic flow. In terms of mechanism of action, the diverse biological effects of G-Rg2 result from its background-dependent regulation of key intracellular signaling pathways such as AMPK, MAPK, NF-κB and PI3K-AKT-mTOR, which are interconnected to form a complex regulatory network. This plasticity in pathway regulation confers bidirectional pharmacological properties of G-Rg2, which induces apoptosis through inhibition of the PI3K-AKT-mTOR pathway in MCF-7 breast cancer cells, whereas it activates the same pathway to promote cell survival in cardiomyocytes and neurons under ischemic conditions. Metabolomics and multiomics studies in animal models suggest that G-Rg2 regulates metabolic networks and multiple signaling pathways simultaneously in a complex disease environment, suggesting that G-Rg2 is most likely a network-level regulatory mode rather than a linear single-target action. The poor oral bioavailability, rapid systemic clearance, stereochemical complexity due to the 20(R)/20(S) isomers, and insufficient long-term safety data of G-Rg2 have hindered its translation into clinical trials. Based on existing mechanism-related research on G-Rg2, this review proposes a network-based regulatory framework and offers specific suggestions to enhance the bioavailability and targeting of G-Rg2, providing actionable directions for its clinical translation.